Moderna (MRNA) Competitor Comparison
We are evaluating the key criteria listed to compare Moderna (MRNA) against its competitors in the Biotechnology industry.
Market Capitalization
4 / 368Gross Profits
1 / 278Total Revenue
3 / 300EBITDA
337 / 337Free Cashflow
351 / 352Quick Ratio
280 / 357Earnings per Share
313 / 359Dividend yield
0 / 6Total Cash
3 / 358Performance 3 years
261 / 368Performance 5 years
74 / 368Performance 10 years
72 / 368Linearity 3 years
176 / 368Linearity 5 years
32 / 368Linearity 10 years
21 / 368Total Rank
1 / 368Dividend Rank
209 / 368Valuation Rank
4 / 368Piotroski Rank
160 / 368Muliplier Rank
16 / 368EBITDA - MRNA ranking 337 / 337
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.